Tesamorelin — Literature-Reported Ranges & Study Protocols

Read this first

Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.

Compound at a glance

Class: Stabilised GHRH analogue
Reported half-life: Approximately 26–38 minutes
Routes used in the literature: Subcutaneous
Also written as: —

What the published studies reported

Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.

Phase 3 visceral adipose tissue trials

Reported quantity: 2 mg subcutaneously
Frequency: Once daily
Study duration: 26 weeks, with 52-week extension arms

Visceral fat reduction was measured by CT at week 26 in the pivotal studies.

Cognitive and IGF-1 substudies

Reported quantity: 1–2 mg
Frequency: Once daily
Study duration: 20 weeks in the published cognition work

IGF-1 was tracked as the pharmacodynamic marker across these arms.

Dosage chart

These figures match the published chart for this compound on peptidedosages.com, including the reconstitution volume, resulting concentration, insulin-syringe units and the staged schedule. Educational reference only — not instructions, and not medical advice.

Tesamorelin · 10 mg Vial

Tesamorelin is dosed at 1 mg–2 mg daily by subcutaneous injection in educational protocols, typically at night. A 10 mg vial reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.

Reconstitute: Add 3.0 mL bacteriostatic water per 10 mg vial → ~3.33 mg/mL concentration.
Standard daily dose: 2 mg (2000 mcg) once daily subcutaneously (FDA-approved protocol).
Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.
Storage: Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F); reconstituted: refrigerate and use within 7 days with bacteriostatic water.

Standard FDA-Approved Protocol (3.0 mL = ~3.33 mg/mL)

Week	Daily Dose (mg / mcg)	Units (per injection) (mL)
Week 1	1 mg / 1000 mcg	30 units (0.30 mL)
Weeks 2–12+	2 mg / 2000 mcg	60 units (0.60 mL)

Source chart on peptidedosages.com

Mixed with 3 ml of bacteriostatic water

The same arithmetic for every vial size Tesamorelin is supplied in, using a fixed 3 ml of bacteriostatic water. One unit on a U-100 insulin syringe is 0.01 ml, so the unit column below is simply the volume that carries the reported amount. Educational arithmetic only — not instructions, and not medical advice.

Tesamorelin · 3 ml bacteriostatic water

Vial size	Concentration	Per 1 unit	2 mg =
2 mg	0.67 mg/ml	7 mcg	300 units
5 mg	1.67 mg/ml	17 mcg	120 units
10 mg	3.33 mg/ml	33 mcg	60 units

Unit columns use the range reported for this compound (2 mg). Only the vial sizes this compound is actually supplied in are shown, and every figure assumes exactly 3 ml of bacteriostatic water. For any other volume, use the reconstitution calculator.

Reconstitution maths

Research vials are commonly 2 mg or 10 mg. 10 mg in 2 mL gives 5 mg/mL; the trial figure of 2 mg corresponds to 0.4 mL at that concentration.

Open the reconstitution calculator

How to read these figures

Trial participants were a specific clinical population; the figures describe that population, not a general one.
Glucose-metabolism changes were monitored throughout the pivotal trials.
Effects reported in the literature reversed after discontinuation.

Sources and citations

These are the published records the figures on this page are drawn from. Each one describes what researchers administered, in which model or population, and over what period. Quantities reported in a study are specific to that study's design and are not transferable guidance.

[1]
Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV
Falutz J, Allas S, Blot K, et al. · N Engl J Med · 2007 · DOI 10.1056/NEJMoa072375
HIV-infected patients with abdominal fat accumulation self-administered daily 2 mg subcutaneous tesamorelin injections for 26 weeks to assess reduction of visceral adipose tissue.
View the record
[2]
Effects of Tesamorelin, a Growth Hormone-Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension
Falutz J, Potvin D, Mamputu JC, et al. · J Acquir Immune Defic Syndr · 2010 · DOI 10.1097/QAI.0b013e3181cbdaff
Extension trial of daily 2 mg subcutaneous tesamorelin dosing over an additional 26-52 weeks to evaluate durability of visceral fat reduction and safety.
View the record
[3]
Effects of Tesamorelin (TH9507), a Growth Hormone Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat: A Pooled Analysis of Two Multicenter, Double-Blind Placebo-Controlled Phase 3 Trials with Safety Extension Data
Falutz J, Mamputu JC, Potvin D, et al. · J Clin Endocrinol Metab · 2010 · Pooled Phase 3 Analysis
Pooled analysis of two phase 3 trials of daily 2 mg subcutaneous tesamorelin injections confirming visceral fat-reduction efficacy and long-term safety.
View the record

Search the databases yourself

Read the Tesamorelin research brief

Other growth hormone compounds

AOD-9604hGH fragment 176-191 CJC-1295 (no DAC)Tetra-substituted GHRH (1-29) analogue CJC-1295 (no DAC) + IpamorelinGHRH analogue + selective ghrelin-receptor agonist blend CJC-1295 with DACGHRH analogue with albumin-binding drug affinity complex

All research protocols

Peptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.